Search results for "Liposarcoma"

showing 10 items of 25 documents

Large left ventricular metastatis in patient with liposarcoma.

2014

Abstract Metastasis to the heart and pericardium are rare. We present a 44-year-old male with pleural dedifferentiated liposarcoma and multiple metastases, with no previous cardiological history and/or cardiac symptoms. A transthoracic echocardiogram during the advanced stage of disease showed a lobulated, large and mobile mass, with homogeneous echogenicity, attached to the basal posterior wall of the left ventricle via a broad base and with intracavitary growth. This mass extends to inferolateral and inferoseptal wall of the left ventricle.

AdultMalemedicine.medical_specialtyTime FactorsLarge left ventricular metastasiBiopsyHeart VentriclesPleural Neoplasms030204 cardiovascular system & hematologyDoppler echocardiographyLiposarcomaMetastasisHeart Neoplasms03 medical and health sciencesFatal Outcome0302 clinical medicineHumansMedicinePericardium030212 general & internal medicinePleural Neoplasmheart metastases liposarcomamedicine.diagnostic_testbusiness.industryEchogenicityGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEchocardiography DopplerTumor Burdenmedicine.anatomical_structureVentricleliposarcomaDisease Progressioncardiovascular systemRadiologyTransthoracic echocardiogramTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusiness
researchProduct

BMI as a risk factor for toxicities in patients with advanced soft tissue sarcoma treated with trabectedin.

2017

e22517 Background: Since the first steps of its clinical development, trabectedin was noticed to be extremely active against myxoid liposarcoma (MLS), whose pathogenesis seems to be associated to the presence of the t(12;16)(q13;p11) translocation, resulting in the expression of FUS-DDIT3 fusion genes. Therefore, the drug seems to induce a maturation of MLS lipoblasts, with transition of the residual spindle non-lipogenic cells into mature vacuolated lipoblasts. This effect could be prevented by the increase of leptin circulating levels in obese patients. For these reasons we designed this retrospective analysis in order to evaluate the BMI status (measure of total adipose content) as a pr…

OncologyCancer Researchmedicine.medical_specialtyMyxoid liposarcomabusiness.industrySoft tissue sarcomamedicine.diseasePathogenesisOncologyInternal medicinemedicineIn patientRisk factorbusinessTrabectedinmedicine.drugJournal of Clinical Oncology
researchProduct

Immunohistochemical detection of EWS and FLI-1 proteinss in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2…

2001

The molecular analysis of the t(11;22) rearrangement involving EWS/FLI-1 genes is likely to be of diagnostic value in Ewing sarcoma (ES) and primitive neuroectodermal tumors (PNET). The objective of the current study was to analyze the immunohistochemical expression of the EWS and FLI-1 proteins in a group of small round-cell tumors (SRCT) to determine their specificity and relevance in their differential diagnosis. Forty-eight cases-10 conventional ES, 4 large-cell ES, 5 PNET, 9 neuroblastomas (NB), 6 undifferentiated synovial sarcomas (SS), 5 rhabdomyosarcomas (RB), 5 non-Hodgkin lymphomas (NHL), 1 round-cell liposarcoma, and 3 mesenchymal chondrosarcomas-were analyzed. Immunocytochemistr…

HistologyImmunocytochemistryCD99Sarcoma EwingLiposarcomaBiology12E7 AntigenSensitivity and SpecificityHeterogeneous-Nuclear RibonucleoproteinsPathology and Forensic Medicinechemistry.chemical_compoundAntigenAntigens CDProto-Oncogene ProteinsmedicineHumansNeuroectodermal Tumors PrimitiveProto-Oncogene Protein c-fli-1medicine.diseaseImmunohistochemistryDNA-Binding ProteinsMedical Laboratory TechnologyAntigen retrievalchemistryRibonucleoproteinsCancer researchTrans-ActivatorsImmunohistochemistrySarcomaDifferential diagnosisRNA-Binding Protein EWSCell Adhesion MoleculesApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

2018

Abstract Purpose: Nilotinib plus doxorubicin showed to be synergistic regarding apoptosis in several sarcoma cell lines. A phase I/II trial was thus designed to explore the feasibility of nilotinib as coadjuvant of doxorubicin by inhibiting MRP-1/P-gp efflux activity. The phase I part of the study is presented here. Patients and Methods: Nilotinib 400 mg/12 hours was administered in fixed dose from day 1 to 6, and doxorubicin on day 5 of each cycle. Three dose escalation levels for doxorubicin at 60, 65, and 75 mg/m2 were planned. Cycles were repeated every 3 weeks for a total of 4 cycles. Eligible subtypes were retroperitoneal liposarcoma, leiomyosarcoma, and unresectable/metastatic high-g…

Male0301 basic medicineLeiomyosarcomaOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentDrug Evaluation PreclinicalApoptosisLiposarcomaNeutropeniaMice03 medical and health sciences0302 clinical medicineCell Line TumorInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineAnimalsHumansCell ProliferationNeoplasm StagingChemotherapybusiness.industrySarcomamedicine.diseasePyrimidines030104 developmental biologyOncologyNilotinibChemotherapy AdjuvantDoxorubicin030220 oncology & carcinogenesisFemaleSarcomaNeoplasm GradingChondrosarcomabusinessFebrile neutropeniamedicine.drugClinical Cancer Research
researchProduct

Retroperitoneale Sarkome: Diagnostik und Therapie

2006

Background Due to the fact that there are no distinct anatomical compartments, retroperitoneal sarcomas are moreover diagnosed with evidence of large tumors and infiltration of adjacent organs. In spite of improvement of the diagnostic facilities and surgical techniques, quite frequently local recurrences with unfavourable prognosis turn up even after complete removal. It was the aim of this study to analyze diagnosis, therapy and long-term prognosis in patients with retroperitoneal sarcomas over a period of 10 years. Patients and methods Between January 1995 and January 2005, 379 patients underwent surgery for a primary retroperitoneal tumor at our clinic. Among the 67 (17.1 %) malignant l…

Leiomyosarcomamedicine.medical_specialtyPathologyRetroperitoneal sarcomasbusiness.industrymedicine.medical_treatmentRetrospective cohort studyLiposarcomamedicine.diseasemedicineSurgeryRadiologyEmbolizationSarcomabusinessSurvival rateNeoadjuvant therapyZentralblatt für Chirurgie
researchProduct

Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.

2017

International audience; Purpose. - Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. Patients and methods. - Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy …

LeiomyosarcomaMaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment030232 urology & nephrologyParatesticular tumor[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine0302 clinical medicineMedicineOrchiectomy[ SDV.IB ] Life Sciences [q-bio]/BioengineeringPatternsFederationRapidarc[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingCancerAged 80 and overSpermatic CordSarcomaRadiotherapy DosageLiposarcomaMiddle AgedRetroperitoneal Sarcoma3. Good healthmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisGenital Neoplasms MaleSoft-Tissue Sarcoma[SDV.IB]Life Sciences [q-bio]/BioengineeringSarcomaRadiodermatitisReoperationmedicine.medical_specialtyPrognostic-Factors[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSpermatic cord03 medical and health sciencesTherapeutic approachHumansRadiology Nuclear Medicine and imagingIMRTAgedRetrospective StudiesRadiotherapybusiness.industryCancermedicine.diseaseRadiation-TherapySurgeryRadiation therapyRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessLigationOrchiectomyRare diseaseFollow-Up StudiesCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
researchProduct

PML down-regulation in soft tissue sarcomas

2010

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantl…

LeiomyosarcomaPathologymedicine.medical_specialtyPhysiologysoft tissue tumorSettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationLiposarcomaPromyelocytic Leukemia ProteinPleomorphic LiposarcomaPML sarcomasPromyelocytic leukemia proteinmedicineHumanssarcomasneoplasmsMyxoid liposarcomaPMLbiologybusiness.industrySoft tissue sarcomaTumor Suppressor ProteinsNuclear ProteinsSarcomaCell BiologyAnatomymedicine.diseaseImmunohistochemistrySynovial sarcomabody regionsbiology.proteinSarcomabusinessTranscription Factors
researchProduct

Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report

2019

Highlights • We describe a case report of large retroperitoneal dedifferentiated liposarcoma totally treated by laparoscopic surgery. • In literature we found few cases of laparoscopic treatment only for Well-Differentiated liposarcoma. • To our knowledge this is the first description of Dedifferentiated liposarcoma completely treated with laparoscopic technique. • Literature review was performed to identify outcomes and advantages of laparoscopic approach for.

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentLiposarcomaArticle03 medical and health sciences0302 clinical medicineOpen ResectionBiopsymedicine3D laparoscopic surgeryLaparoscopyneoplasmsReduction (orthopedic surgery)medicine.diagnostic_testbusiness.industryCosmesisSoft tissuemedicine.diseasebody regionsDedifferentiated liposarcomaRetroperitoneal liposarcoma030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgeryRadiologybusinessInternational Journal of Surgery Case Reports
researchProduct

RETROVESICAL MASS IN MEN

1999

We review the differential diagnosis and treatment of retrovesical masses in men.During the last 8 years 21 male patients 3 to 79 years old (mean age 47.1) presented with symptoms or signs of a retrovesical mass. Clinical features and diagnostic findings were reviewed, and related to surgical and histopathological findings.The retrovesical masses included prostatic utricle cyst in 3 cases, prostatic abscess in 1, seminal vesicle hydrops in 6, seminal vesicle cyst in 2, seminal vesicle empyema in 3, large ectopic ureterocele in 1, myxoid liposarcoma in 1, malignant fibrous histiocytoma in 1, fibrous fossa obturatoria cyst in 1, hemangiopericytoma in 1 and leiomyosarcoma in 1. In 17 patients …

LeiomyosarcomaAdultMalePathologymedicine.medical_specialtyAdolescentUrologyUrinary BladderDiagnosis DifferentialSeminal vesiclemedicineHumansCystChildAgedRetrospective StudiesHemangiopericytomaMyxoid liposarcomabusiness.industryDecision TreesMiddle Agedmedicine.diseaseProstatic utricleEmpyemamedicine.anatomical_structureChild PreschoolDifferential diagnosisGenital Diseases MalebusinessThe Journal of Urology
researchProduct